Skip to main content

Table 1 Patient and treatment characteristics

From: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy

n = 110 patients Median / n (% / range)
Age 59.4 (25–82)
Sex
 Male 64 (58.2)
 Female 44 (44.0)
ECOG
 0 77 (70.0)
 1 26 (23.6)
 2 6 (5.5)
 3 1 (0.9)
Number of brain metastases median: 2 (1–30)
 1 47 (42.7)
 2–4 53 (48.1)
 > 4 10 (9.0)
BRAF status
 positive 57 (48.2)
 negative/unknown 46 (41.8) / 7 (6.3)
extracranial metastases
 yes 83 (75.5)
 no 27 (24.5)
volume of brain metastases
 ≥ 1.5 cc 55 (50.0) 1.5–24.54 cc
 < 1.5 cc 55 (50.0) 0.05–1.4 cc
RT regimen
 SRS 95 (86.4)
 SRT 15 (13.6)
Concomitant systemic therapy
 IT 67 (60.9)
 TT 34 (30.9)
 combination 9 (8.2)
  1. Abbreviations: SRS Stereotactic radiosurgery, SRT Stereotactic radiotherapy, IT Immunotherapy, TT Targeted therapy